ATA448678A - Verfahren zur herstellung des neuen tetrahydroisoxazol(5a,4-c)pyridin-3-ols und von dessen salzen - Google Patents

Verfahren zur herstellung des neuen tetrahydroisoxazol(5a,4-c)pyridin-3-ols und von dessen salzen

Info

Publication number
ATA448678A
ATA448678A AT0448678A AT448678A ATA448678A AT A448678 A ATA448678 A AT A448678A AT 0448678 A AT0448678 A AT 0448678A AT 448678 A AT448678 A AT 448678A AT A448678 A ATA448678 A AT A448678A
Authority
AT
Austria
Prior art keywords
tetrahydroisoxazole
ols
pyridine
salts
producing
Prior art date
Application number
AT0448678A
Other languages
English (en)
Other versions
AT368505B (de
Inventor
Povl Krogsgaard-Larsen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of ATA448678A publication Critical patent/ATA448678A/de
Application granted granted Critical
Publication of AT368505B publication Critical patent/AT368505B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
AT0448678A 1977-06-20 1978-06-20 Verfahren zur herstellung des neuen tetrahydroisoxazol(5,4-c)pyridin-3-ols und von dessen salzen AT368505B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2574077 1977-06-20

Publications (2)

Publication Number Publication Date
ATA448678A true ATA448678A (de) 1982-02-15
AT368505B AT368505B (de) 1982-10-25

Family

ID=10232513

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0448678A AT368505B (de) 1977-06-20 1978-06-20 Verfahren zur herstellung des neuen tetrahydroisoxazol(5,4-c)pyridin-3-ols und von dessen salzen

Country Status (14)

Country Link
US (2) US4278676A (de)
EP (4) EP0028017A1 (de)
JP (2) JPS5436275A (de)
AT (1) AT368505B (de)
AU (2) AU3724478A (de)
CA (1) CA1107736A (de)
DK (2) DK270278A (de)
ES (2) ES470912A1 (de)
FI (2) FI781955A7 (de)
IE (1) IE47200B1 (de)
IT (2) IT7868449A0 (de)
NO (3) NO782128L (de)
NZ (1) NZ187615A (de)
ZA (2) ZA783492B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3145474A1 (de) * 1980-11-27 1982-09-02 Kefalas A/S, Koebenhavn-Valby 3-substituierte 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridinverbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3145473A1 (de) * 1980-11-27 1982-08-26 Kefalas A/S, Koebenhavn-Valby 2-substituierte 4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-on-verbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP0083378A1 (de) * 1981-12-22 1983-07-13 Chugai Seiyaku Kabushiki Kaisha Tetrahydronicotinsäureamide, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
GB8314391D0 (en) * 1983-05-24 1983-06-29 Kefalas As Heterocyclic compounds
IT1228426B (it) * 1987-07-20 1991-06-17 Ausimont Spa Perossiacidi eterociclici
US4859666A (en) * 1988-07-06 1989-08-22 Bristol-Myers Company THAZ derivatives for enhancement of cerebral function
CN1043051C (zh) * 1994-07-22 1999-04-21 国际壳牌研究有限公司 制备氢化石蜡的方法
EP1641456B1 (de) 2003-06-25 2010-03-03 H. Lundbeck A/S Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
EP1696959A2 (de) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin-kombinationstherapie zur verbesserung der schlafqualität
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
CA2556870C (en) * 2004-02-18 2014-01-28 Timothy J. Barberich Dopamine-agonist combination therapy for improving sleep quality
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (de) * 2005-01-28 2008-01-23 Merck & Co Inc Polymorphe formen eines gabaa-agonisten
EP1906953A4 (de) * 2005-04-29 2009-05-20 Lundbeck & Co As H Säure- und basensalzformen von gaboxadol
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (de) 2006-09-08 2009-06-17 Braincells, Inc. Kombinationen mit einem 4-acylaminopyridin-derivat
US20100193652A1 (en) * 2009-02-02 2010-08-05 William Stajos Wall Display System And Method Of Providing The Same
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8784835B2 (en) * 2012-07-02 2014-07-22 Trent Austin Method for producing muscimol and/or reducing ibotenic acid from amanita tissue
CN104974175A (zh) * 2014-04-11 2015-10-14 天津药物研究院 一种氨甲基羟异恶唑类似物的制备方法
ES2876350T3 (es) 2014-06-06 2021-11-12 Ovid Therapeutics Inc Métodos para aumentar la inhibición tónica y tratamiento del insomnio secundario
DK3274331T3 (da) * 2015-03-24 2020-03-23 H Lundbeck As Fremstilling af 4,5,6,7-tetrahydroisozaxolo[5,4-c]pyridin-3-ol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
KR20240160666A (ko) 2015-07-17 2024-11-11 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
EP4233861A3 (de) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Zusammensetzungen zur behandlung von essentiellem tremor
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
AU2019345312A1 (en) 2018-09-20 2021-03-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
CN114292224B (zh) * 2022-03-07 2022-05-20 中国农业科学院农产品加工研究所 一种大麻二酚-2-（n-乙酰基）哌啶酸酯及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2784190A (en) * 1952-03-28 1957-03-05 Upjohn Co Alkyl piperidinepropionates
CA762455A (en) * 1962-03-22 1967-07-04 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Pyrido-pyrimidines
US3381016A (en) * 1966-03-04 1968-04-30 Upjohn Co Isoxazolo[5, 4-b]pyridine derivatives and a method for their preparation
DE2221770A1 (de) * 1972-05-04 1973-11-15 Bayer Ag Verfahren zur herstellung von tetrahydropyridinen
DK62791A (da) * 1991-04-09 1992-11-09 Tulip Int As Fremgangsmaade til saltning af koed samt anlaeg til brug ved udoevelse af fremgangsmaaden

Also Published As

Publication number Publication date
NO782128L (no) 1978-12-21
ES470913A1 (es) 1979-02-01
ZA783492B (en) 1979-06-27
NO782127L (no) 1978-12-21
DK270278A (da) 1978-12-21
NZ187615A (en) 1981-12-15
EP0000338B1 (de) 1981-11-25
EP0000338A3 (en) 1979-06-27
DK270378A (da) 1978-12-21
FI781954A7 (fi) 1978-12-21
ES470912A1 (es) 1979-02-01
AT368505B (de) 1982-10-25
ZA783493B (en) 1979-06-27
US4278676A (en) 1981-07-14
JPS5436275A (en) 1979-03-16
CA1107736A (en) 1981-08-25
NO152049B (no) 1985-04-15
EP0000167A1 (de) 1979-01-10
EP0027279A1 (de) 1981-04-22
EP0000338A2 (de) 1979-01-24
FI64376C (fi) 1983-11-10
NO152049C (no) 1985-07-24
IE47200B1 (en) 1984-01-11
AU521040B2 (en) 1982-03-11
EP0028017A1 (de) 1981-05-06
IT7868449A0 (it) 1978-06-20
IT7868450A0 (it) 1978-06-20
US4301287A (en) 1981-11-17
AU3724478A (en) 1980-01-03
FI64376B (fi) 1983-07-29
JPS5436290A (en) 1979-03-16
IE781234L (en) 1978-12-20
FI781955A7 (fi) 1978-12-21
IT1159739B (it) 1987-03-04
NO792839L (no) 1978-12-21
AU3729878A (en) 1980-01-03

Similar Documents

Publication Publication Date Title
AT368505B (de) Verfahren zur herstellung des neuen tetrahydroisoxazol(5,4-c)pyridin-3-ols und von dessen salzen
ATA179380A (de) Verfahren zur herstellung des neuen 11-aza-4-0cladinosyl-6-0-desosaminyl-15-athyl-7,13,14trihydroxy-3,5,7,9,12,14-hexa- methyloxacyclopentadecan-2-ons- und dessen derivaten
AT366374B (de) Verfahren zur herstellung von neuen n3substituierten 5,5-dimethylhydantoinen
AT355047B (de) Verfahren zur herstellung von 1,4:3,6- dianhydro-d-glucit-2-nitrat
AT362499B (de) Verfahren zur herstellung des neuen anti- biotisch wirksamen deosynarasinkomplexes
AT361487B (de) Verfahren zur herstellung von neuen pyrazolo(1, 5c)chinazolinen und ihren salzen
AT358019B (de) Verfahren zur herstellung von neuen 1,3- -diphenoxypropanon-(2)-derivaten
AT358593B (de) Verfahren zur herstellung von neuen 1,2,4- -triazin-5-on-derivaten
AT380883B (de) Verfahren zur herstellung von neuen 1-oxo-1h -thiazolo(3,2-a)pyrimidin-2-carboxamiden
ATA335178A (de) Verfahren zur herstellung von neuen 1-acyl-2- hydroxy-1,3-diaminopropanen und deren salzen
AT343142B (de) Verfahren zur herstellung des neuen o,o-diathyl-o- (n-methoxy-2-nitrobenzimidoyl)-thionophosphorsaureesters
AT362378B (de) Verfahren zur herstellung des neuen 3-cyan-n- -(n,n-dimethylaminopropyl)-iminodibenzyls und dessen saeureadditionssalzen
AT360524B (de) Verfahren zur herstellung von neuen 1,2- benzisothiazolen
AT352697B (de) Verfahren zur herstellung von neuen cyclohexen- (1)-dion-(3,6)-tetraalkyldiketalen
AT361925B (de) Verfahren zur herstellung des neuen n-6-chlor- nicothinoyl-d,1-homocysteinthiolactons und dessen salzen
AT372077B (de) Verfahren zur herstellung von neuen benzylidenderivaten
AT373238B (de) Verfahren zur herstellung des neuen 4-amino-5-
DD132497A1 (de) Verfahren zur herstellung von neuen gona-4,9(10)-dienen
AT373872B (de) Verfahren zur herstellung von 2,2-dialkyl-4-methyl-5,5-dialkyl-3-formyl-3-pyr olinen
ATA91780A (de) Verfahren zur herstellung des neuen 2-benzyl-3(3-dimethylaminopropylthio)-2h-indazols und von dessen salzen
AT363484B (de) Verfahren zur herstellung des neuen 3-cyan-n(n,n-dimethylaminopropyl)-iminodibenzyls und dessen saeureadditionssalzen
AT361626B (de) Verfahren zur herstellung von neuen 7alpha- -methoxy-7beta-(4-substituiert-methylen-1,3- -dithiaethan-2-yl)carboxamido-3-heterocyclisch- thiomethyl-delta3-cehpem-4-carbonsaeuren
ATA463380A (de) Verfahren zur herstellung des neuen 3-cyan-n-(n,n-dimethylaminopropyl)-iminodibenzy s und dessen saeureadditionssalzen
ATA463280A (de) Verfahren zur herstellung des neuen 3-cyan-n- -(n,n-dimethylaminopropyl)-iminodibenzyls und dessen saeureadditionssalzen
ATA707379A (de) Verfahren zur herstellung von neuen 1,1- -dithienyl-(3)-1-hydroxy-alkylhalogeniden

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee